帕薩妥珠單抗

化合物

帕薩妥珠單抗INN:parsatuzumab[1];開發代號:MEGF0444A)是一種人源化單克隆抗體,設計用於治療多種癌症,包括轉移性結直腸癌和非鱗狀非小細胞肺癌。它充當免疫調節劑並與EGFL7結合。[2][3]

帕薩妥珠單抗
單克隆抗體
種類完整抗體
目標EGFL7
臨床資料
ATC碼
  • 未分配
識別資訊
CAS號1312797-14-0
ChemSpider
  • none
UNII
化學資訊
化學式C6560H10130N1758O2046S46
摩爾質量147,836.22 g·mol−1

該藥物由基因泰克/羅氏公司開發。[4]

參考資料

  1. ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2) [2024-03-19]. (原始內容存檔 (PDF)於2016-03-04). 
  2. ^ García‐Carbonero, Rocío; van Cutsem, Eric; Rivera, Fernando; Jassem, Jacek; Gore, Ira; Tebbutt, Niall; Braiteh, Fadi; Argiles, Guillem; Wainberg, Zev A.; Funke, Roel; Anderson, Maria. Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer. The Oncologist. 2017-04, 22 (4) [2024-03-19]. ISSN 1083-7159. PMC 5388369 . PMID 28275117. doi:10.1634/theoncologist.2016-0133. (原始內容存檔於2024-04-22). 
  3. ^ von Pawel, Joachim; Spigel, David R.; Ervin, Thomas; Losonczy, György; Barlesi, Fabrice; Juhász, Erzsébet; Anderson, Maria; McCall, Bruce; Wakshull, Eric; Hegde, Priti; Ye, Weilan. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer. The Oncologist. 2018-06-01, 23 (6) [2024-03-19]. ISSN 1083-7159. PMC 6067939 . PMID 29438092. doi:10.1634/theoncologist.2017-0690. (原始內容存檔於2024-04-20) (英語). 
  4. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Parsatuzumab, American Medical Association.